2,250 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Everence Capital Management Inc.

Everence Capital Management Inc. bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,250 shares of the specialty pharmaceutical company’s stock, valued at approximately $277,000.

Several other hedge funds have also made changes to their positions in JAZZ. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $29,000. EverSource Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC lifted its position in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares during the period. Venturi Wealth Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JAZZ. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. TD Cowen cut their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:JAZZ opened at $122.54 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of 17.26, a PEG ratio of 1.04 and a beta of 0.56. The business has a 50-day moving average price of $121.45 and a 200-day moving average price of $113.89.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.